One Year On, US FDA Generic Drug Cluster Focuses On Facilitating Collaboration
Group Has Made Significant Progress Regarding Data Sharing
Executive Summary
Following its inaugural year, the FDA’s Generic Drug Cluster has formed data sharing arrangements concerning a number of vital indications.
You may also be interested in...
Data Integrity: US FDA Guidance Seeks To Head Off Bioavailability/Bioequivalence Study Problems
Ultimate responsibility for data integrity rests with applicant, even if study is contracted out; testing site management should build a culture of quality, says the guidance, which aims to address the high-profile data integrity problems that have plagued the generic drug industry.
Data Integrity: US FDA Guidance Seeks To Head Off Bioavailability/Bioequivalence Study Problems
Ultimate responsibility for data integrity rests with applicant, even if study is contracted out; testing site management should build a culture of quality, says the guidance, which aims to address the high-profile data integrity problems that have plagued the generic drug industry.
FDA’s Office Of Generic Drugs Gets New Permanent Director And Oversight Designee
Iilun Murphy, a 15-year agency veteran, takes helm of OGD. Jacqueline Corrigan-Curay to assume oversight of the office and report to CDER director.